Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference
June 03, 2019 08:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update
May 13, 2019 08:00 ET
|
Neon Therapeutics, Inc.
Advancing a class-leading position in neoantigen-based therapies with ongoing progress across its multiple clinical-stage programs, pre-clinical pipeline and bioinformatics engine Expect to report in...
Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
May 08, 2019 08:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer
April 08, 2019 07:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the...
Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting
March 31, 2019 15:00 ET
|
Neon Therapeutics, Inc.
Post-Vaccine Immune and Pathologic Markers Associated with Durable Clinical Benefit in Metastatic Melanoma Patient Cohort Top-line Results, Including 52-Week Clinical Outcomes, from Full NT-001 Trial...
Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 11, 2019 07:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported...
Neon Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
March 04, 2019 08:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting
February 27, 2019 19:25 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced...
Neon Therapeutics to Present at 8th Annual Leerink Partners Global Healthcare Conference
February 21, 2019 08:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
Neon Therapeutics Provides Business Update and Outlook for 2019
January 03, 2019 07:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today provided a...